When sleep apnoea device manufacturer ResMed’s share price slumped almost 40 per cent from peak to trough last year on fears that weight loss wonder drug Ozempic would shrink the market for people seeking treatment for sleep disorders, Investors Mutual’s Daniel Moore was a buyer.

He saw ResMed’s weakened share price as an opportunity to acquire a stock whose fortunes more bearish pundits had got wrong.